SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 28, 2005
PHARMOS CORPORATION
(Exact name of Registrant as Specified in its Charter)
Nevada | 0-11550 | 36-3207413 |
(States or Other Jurisdiction | (Commission file Number) | (IRS Employer |
of Incorporation) | | Identification No.) |
99 Wood Avenue South, Suite 311, Iselin, NJ | 08830 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants’ telephone number, including area code (732) 452-9556
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-2 under the Exchange Act (17 CFR 240.14a-2)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
Due to circumstances beyond the control of Pharmos Corporation, its third-party webcast service provider was unable to webcast the entire Pharmos conference call that took place on April 28, 2005, during which Pharmos discussed its financial results for the first quarter ended March 31, 2005. The webcast service provider is also unable to make the entire conference call available by web archive. A transcript of the April 28, 2005 Pharmos conference call is attached hereto.
Item 9.01 Financial Statements and Exhibits.
Exhibits
99.1 | Transcript of Pharmos Corporation conference call of April 28, 2005. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 29th day of April, 2005.
PHARMOS CORPORATION |
|
|
By: /s/ James A. Meer |
Name: James A. Meer |
Title: Senior Vice President and Chief Financial Officer |
